Signals 08: June 2026

H1 Roundup, Wave, Nyxoah, Butterfly Network, Shiratronics, Aurenar, SCI Ventures

Welcome back to Signals, a members-only newsletter analyzing key commercial developments across the neurotech industry each month.

Following May’s roundup featuring headlines from Mobia, Medtronic/SPR Inspire, Galvani, Oura, Neurovalens, Ampa, and Neurosoft, this edition covers commercial highlights from June 2026.

• Wave Clears Personalized PTSD Neuromodulation

• Nyxoah Raises $95M for Genio’s US Launch

• Butterfly Builds the Ultrasound Infrastructure Layer

• Shiratronics Completes Enrollment in Pivotal, announces new CPT codes

• Aurenar gets FDA breakthrough nod for critical care wearable

• Craig Hospital joins SCI Ventures as an Alliance Partner, advancing impact investing model

Before we dive in, here is a quick roundup of some of the year’s most important stories we’ve covered so far this year in Signals.

• BCI: Motif/Mint Epia Axoft Nia Paradromics, Precision, MDT, Science, Neurosoft

• Implanted: Mobia, Medtronic/SPR, Inspire, Galvani, Spiros

• Consumer: Oura Neurable Meta WHOOP, BrainCo, NaoX, Apple, Q.ai

• Mental Health: Neurovalens Ampa, Salma, Radial, Kintsugi, Neurolief, Brainsway

• Non-Invasive: Noctrix, Bioness, Neuraxis, Surf,

• Other: Brainlab, Biological Computing Company, Omniscient

(Reminder: Unlock free access by sharing this newsletter with your network!)